opDNA® vs plasmid DNA: A technical evaluation of IVT mRNA manufacture

As mRNA production scales for global vaccine and therapeutic applications, pDNA manufacturing struggles to meet demand, with inconsistent yields, risk of batch failure and need for cell banking, further slowing down the process. These challenges along with increased demand have accelerated the shift toward synthetic DNA templates, which provide a faster, cleaner, and more scalable solution tailored to the needs of mRNA manufacturing. By eliminating bacterial fermentation systems, synthetic DNA removes the risk of endotoxin contamination, avoids unwanted antibiotic resistance genes, and allows for inclusion of complex sequences.

This technical note highlights how 4basebio’s opDNA®, a linear, double-stranded DNA template optimized for in vitro transcription, streamlines production and accelerates the development of next-generation mRNA medicines.